4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Total Non-Current Liabilities data on file, last reported at $60.9 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $60.9 million, up 32.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.9 million (up 32.99% YoY), and the FY2025 annual result was $60.9 million, up 23.38% from the prior year.
• Total Non-Current Liabilities steadied at $60.9 million in Q1 2026 per FDMT's latest filing, from $60.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $60.9 million in Q1 2026 and troughed at $25.4 million in Q1 2023.
• A 5-year average of $39.4 million and a median of $31.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities jumped 115.94% in 2022, then decreased 12.02% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $30.5 million in 2022, then advanced by 4.35% to $31.8 million in 2023, then surged by 55.18% to $49.4 million in 2024, then advanced by 23.38% to $60.9 million in 2025, then rose by 0.06% to $60.9 million in 2026.
• Business Quant data shows FDMT's Total Non-Current Liabilities at $60.9 million in Q1 2026, $60.9 million in Q4 2025, and $54.7 million in Q3 2025.